Q4 2026 Aarti Drugs Ltd Earnings Call Transcript
Key Points
- Aarti Drugs Ltd (BOM:524348) reported a 6% year-on-year and 20% quarter-on-quarter revenue growth in Q4 FY26, indicating a strong recovery.
- The company achieved a significant 72% quarter-on-quarter growth in EBITDA, reflecting improved operational efficiency.
- The formulation segment saw a 41% year-on-year revenue increase, with exports contributing 69% to this growth.
- The new methylamines plant ramped up to nearly 1,000 tons per month, enhancing self-sufficiency and supporting margin improvement.
- Export contribution increased from 35% in FY25 to 38% in FY26, with a notable rise in regulated market sales, showcasing the company's ability to meet international standards.
- The company faced challenges due to elevated input costs, including crude and gas-based raw materials, impacting overall profitability.
- Export revenue declined by 7% year-on-year, indicating challenges in international markets.
- The salicylic acid segment remained a laggard due to equipment delays and variable losses, leading to a temporary production halt.
- The antibiotic segment faced potential demand challenges due to elevated raw material prices, which could impact domestic sales.
- The ongoing West Asia war and its impact on raw material availability, particularly ammonia, posed operational challenges.
Ladies and gentlemen, good day and welcome to Aarti Drugs Limited Q4 FY26 Earnings Conference Call. This conference call may contain forward-looking statements about the company which are based on the beliefs, opinions and expectations of the company as on date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentations and rules. Should you need assistance in the conference call, please signal an operator by pressing star and zero on your touchstone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Ajish Patil, COO and CFO from RP Drugs Limited.
Thank you and over to you Mr. Patil.
Thank you.
Very good morning and welcome. To the Q4 and FY26 Earnings Conference Call of RT Trust Limited.
Joining me
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
